Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection
- PMID: 11454922
Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection
Abstract
Previously, we showed that long-circulating polyethylene glycol (PEG)-liposomes are cleared rapidly from the circulation when injected repeatedly in the same animal. In this article, we describe the effects of PEG-coating, the circulation time, the lipid dose, and the presence of encapsulated doxorubicin on the pharmacokinetics upon repeated injection in rats. Furthermore, the role of liver and splenic macrophages was investigated. Liposomes without PEG-coating also showed the so-called "enhanced clearance effect": blood levels at 4 h post injection decreased from 62.8 +/- 13.7% of injected dose (%ID) after the first injection to 0.54 +/- 0.21%ID after the second injection. This decrease was independent of the circulation time of the first dose. Decreasing the first lipid dose of PEG-liposomes to 0.05 micromol/kg still led to enhanced clearance of a second dose of 5 micromol/kg. No changes in pharmacokinetics were observed when the second dose was 50 micromol/kg. When hepatosplenic macrophages were depleted, no enhanced clearance of repeated liposome injections was observed. A dose of doxorubicin containing PEG-liposomes (Doxil), injected 1 week after injection of empty PEG-liposomes, was cleared rapidly from the circulation in rats. Our results indicate that hepatosplenic macrophages play an essential role in the enhanced clearance effect and that the change in pharmacokinetic behavior upon repeated injection is a general characteristic of liposomes, unrelated to the presence of PEG. Therefore, these findings may have a considerable impact on the clinical application of liposomal formulations that are administered repeatedly.
Similar articles
-
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.J Control Release. 2006 Oct 27;115(3):251-8. doi: 10.1016/j.jconrel.2006.08.017. Epub 2006 Sep 3. J Control Release. 2006. PMID: 17045355
-
Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose.J Pharmacol Exp Ther. 2000 Jun;293(3):996-1001. J Pharmacol Exp Ther. 2000. PMID: 10869403
-
Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.Int J Pharm. 2012 Oct 15;436(1-2):636-43. doi: 10.1016/j.ijpharm.2012.07.049. Epub 2012 Jul 28. Int J Pharm. 2012. PMID: 22850293
-
In vivo applications of PEG liposomes: unexpected observations.Crit Rev Ther Drug Carrier Syst. 2001;18(6):551-66. Crit Rev Ther Drug Carrier Syst. 2001. PMID: 11789675 Review.
-
Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.Int J Pharm. 2008 Apr 16;354(1-2):56-62. doi: 10.1016/j.ijpharm.2007.11.005. Epub 2007 Nov 9. Int J Pharm. 2008. PMID: 18083313 Review.
Cited by
-
Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes.Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27528-27539. doi: 10.1073/pnas.2006186117. Epub 2020 Oct 16. Proc Natl Acad Sci U S A. 2020. PMID: 33067394 Free PMC article.
-
Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats.Sci Rep. 2023 Dec 6;13(1):21501. doi: 10.1038/s41598-023-48742-w. Sci Rep. 2023. PMID: 38057444 Free PMC article.
-
Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol.Sci Rep. 2016 Jan 5;6:18423. doi: 10.1038/srep18423. Sci Rep. 2016. PMID: 26728491 Free PMC article.
-
Biomimetic Functional Nanocomplexes for Photothermal Cancer Chemoimmunotheranostics.Small Sci. 2024 Aug 19;4(10):2400324. doi: 10.1002/smsc.202400324. eCollection 2024 Oct. Small Sci. 2024. PMID: 40212244 Free PMC article.
-
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.J Pharm Sci. 2011 Jan;100(1):38-52. doi: 10.1002/jps.22243. J Pharm Sci. 2011. PMID: 20575003 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources